While clinical use of curcumin is limited by poor bioavailability and PAINS concerns, our results support the rationale for developing curcumin analogs or PAR-2–specific small molecules as adjuncts in CRC therapy. This evidence concerns the gene F2RL1 and colorectal carcinoma.